199 related articles for article (PubMed ID: 1937786)
1. The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections.
Martinez J; Campetella O; Frasch AC; Cazzulo JJ
Infect Immun; 1991 Nov; 59(11):4275-7. PubMed ID: 1937786
[TBL] [Abstract][Full Text] [Related]
2. Trypanosoma cruzi: immunological cross-reactivity of the major cysteinyl proteinase (cruzipain) with a parasite cytosol acidic antigen (FIV).
Cerban FM; Motran C; Laderach D; Gea S; Gruppi A; Vottero-Cima E
Acta Trop; 1994 Dec; 58(3-4):337-43. PubMed ID: 7709872
[TBL] [Abstract][Full Text] [Related]
3. Exoantigens from trypanosoma cruzi contain cruzipain.
Gruppi A; Cerbán FM; Vottero-Cima E
Acta Trop; 1997 Feb; 63(2-3):141-9. PubMed ID: 9088427
[TBL] [Abstract][Full Text] [Related]
4. The reactivity of sera from chagasic patients against different fragments of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, suggests the presence of defined antigenic and catalytic domains.
Martínez J; Campetella O; Frasch AC; Cazzulo JJ
Immunol Lett; 1993 Feb; 35(2):191-6. PubMed ID: 7685319
[TBL] [Abstract][Full Text] [Related]
5. Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII).
Laderach D; Cerban F; Motran C; Vottero de Cima E; Gea S
Int J Parasitol; 1996 Nov; 26(11):1249-54. PubMed ID: 9024869
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Trypanosoma cruzi cysteine proteinase.
Arnholdt AC; Scharfstein J
Res Immunol; 1991 Feb; 142(2):146-51. PubMed ID: 1714087
[No Abstract] [Full Text] [Related]
7. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
Schnapp AR; Eickhoff CS; Scharfstein J; Hoft DF
Microbes Infect; 2002 Jul; 4(8):805-13. PubMed ID: 12270727
[TBL] [Abstract][Full Text] [Related]
8. Identity of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi and an antigen (Ag163B6) isolated with a monoclonal antibody.
Malchiodi EL; Chiaramonte MG; Martínez JA; Zwirner NW; Margni RA; Cazzulo JJ
Immunol Lett; 1993 Jan; 35(1):59-62. PubMed ID: 8458637
[TBL] [Abstract][Full Text] [Related]
9. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
Front Immunol; 2020; 11():1279. PubMed ID: 32695105
[TBL] [Abstract][Full Text] [Related]
10. Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes.
Morrot A; Strickland DK; Higuchi Mde L; Reis M; Pedrosa R; Scharfstein J
Int Immunol; 1997 Jun; 9(6):825-34. PubMed ID: 9199965
[TBL] [Abstract][Full Text] [Related]
11. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase.
Arnholdt AC; Piuvezam MR; Russo DM; Lima AP; Pedrosa RC; Reed SG; Scharfstein J
J Immunol; 1993 Sep; 151(6):3171-9. PubMed ID: 7690795
[TBL] [Abstract][Full Text] [Related]
12. Trypanosoma cruzi serinecarboxipeptidase is a sulfated glycoprotein and a minor antigen in human Chagas disease infection.
Soprano LL; Parente JE; Landoni M; Couto AS; Duschak VG
Med Microbiol Immunol; 2018 Apr; 207(2):117-128. PubMed ID: 29274017
[TBL] [Abstract][Full Text] [Related]
13. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
[TBL] [Abstract][Full Text] [Related]
14. Trypanosoma cruzi: identification of specific epimastigote antigens by human immune sera.
Morgado MG; Ivo-dos-Santos J; Pinho RT; Argüelles E; Rezende JM; Galvão-Castro B
Mem Inst Oswaldo Cruz; 1989; 84(3):309-14. PubMed ID: 2485213
[TBL] [Abstract][Full Text] [Related]
15. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
16.
Chain CY; Pires Souto DE; Sbaraglini ML; Labriola CA; Daza Millone MA; Ramirez EA; Cisneros JS; Lopez-Albizu C; Scollo K; Kubota LT; Ruiz AM; Vela ME
ACS Infect Dis; 2019 Nov; 5(11):1813-1819. PubMed ID: 31538468
[No Abstract] [Full Text] [Related]
17. IgG antibody reactivity with Trypanosoma cruzi and Leishmania antigens in sera of patients with Chagas' disease and leishmaniasis.
Chiller TM; Samudio MA; Zoulek G
Am J Trop Med Hyg; 1990 Dec; 43(6):650-6. PubMed ID: 2125177
[TBL] [Abstract][Full Text] [Related]
18. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi.
Cazzulo JJ; Stoka V; Turk V
Biol Chem; 1997 Jan; 378(1):1-10. PubMed ID: 9049059
[TBL] [Abstract][Full Text] [Related]
19. Epitopes common to Trypanosoma cruzi and mammalian tissues are recognized by sera from Chagas' disease patients: prognosis value in Chagas disease.
Laucella SA; de Titto EH; Segura EL
Acta Trop; 1996 Dec; 62(3):151-62. PubMed ID: 9025983
[TBL] [Abstract][Full Text] [Related]
20. Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review.
Duschak VG; Couto AS
Curr Med Chem; 2009; 16(24):3174-202. PubMed ID: 19689291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
